These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21600312)

  • 1. Refractory vasculitis.
    Rutgers A; Kallenberg CG
    Autoimmun Rev; 2011 Sep; 10(11):702-6. PubMed ID: 21600312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
    Rutgers A; Kallenberg CG
    Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rituximab for the treatment of ANCA associated vasculitis: the future today?].
    Alba MA; Flores-Suárez LF
    Reumatol Clin; 2011 Dec; 7 Suppl 3():S41-6. PubMed ID: 22115869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.
    Lovric S; Erdbruegger U; Kümpers P; Woywodt A; Koenecke C; Wedemeyer H; Haller H; Haubitz M
    Nephrol Dial Transplant; 2009 Jan; 24(1):179-85. PubMed ID: 18685144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
    Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
    Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.
    Keogh KA; Wylam ME; Stone JH; Specks U
    Arthritis Rheum; 2005 Jan; 52(1):262-8. PubMed ID: 15641078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.
    Holle JU; Gross WL
    J Autoimmun; 2009; 32(3-4):163-71. PubMed ID: 19345067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in ANCA-associated vasculitis: fad or fact?
    Fervenza FC
    Nephron Clin Pract; 2011; 118(2):c182-8; discussion c188. PubMed ID: 21160229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based management of ANCA vasculitis.
    Carruthers D; Sherlock J
    Best Pract Res Clin Rheumatol; 2009 Jun; 23(3):367-78. PubMed ID: 19508944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and pathological characteristics and outcomes of Chinese patients with primary anti-neutrophil cytoplasmic antibodies-associated systemic vasculitis with immune complex deposition in kidney.
    Yu F; Chen M; Wang SX; Zou WZ; Zhao MH; Wang HY
    Nephrology (Carlton); 2007 Feb; 12(1):74-80. PubMed ID: 17295665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current state of biologicals in the management of systemic vasculitis.
    Lamprecht P; Till A; Steinmann J; Aries PM; Gross WL
    Ann N Y Acad Sci; 2007 Sep; 1110():261-70. PubMed ID: 17911441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasculitis in the seriously ill patient: diagnostic approaches and therapeutic options in ANCA-associated vasculitis.
    Schmitt WH; Gross WL
    Kidney Int Suppl; 1998 Feb; 64():S39-44. PubMed ID: 9475487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Gao Y; Zhao MH
    Nephrology (Carlton); 2009 Feb; 14(1):33-41. PubMed ID: 19335842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis].
    Tervaert JW; Stegeman CA
    Ned Tijdschr Geneeskd; 2003 Nov; 147(46):2265-7. PubMed ID: 14655291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CARI guidelines. ANCA serology in the diagnosis and management of ANCA-associated renal vasculitis.
    Luxton G; Langham R;
    Nephrology (Carlton); 2008 Jul; 13 Suppl 2():S17-23. PubMed ID: 18713120
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic vasculitis treatment and monitoring update, 2008.
    Yazici Y
    Bull NYU Hosp Jt Dis; 2008; 66(3):228-30. PubMed ID: 18937637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
    Cartin-Ceba R; Fervenza FC; Specks U
    Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
    Guerry MJ; Brogan P; Bruce IN; D'Cruz DP; Harper L; Luqmani R; Pusey CD; Salama AD; Scott DG; Savage CO; Watts RA; Jayne DR
    Rheumatology (Oxford); 2012 Apr; 51(4):634-43. PubMed ID: 21613248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.